1. Home
  2. IMUX vs BYSI Comparison

IMUX vs BYSI Comparison

Compare IMUX & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • BYSI
  • Stock Information
  • Founded
  • IMUX 2016
  • BYSI 2010
  • Country
  • IMUX United States
  • BYSI United States
  • Employees
  • IMUX N/A
  • BYSI N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • BYSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • BYSI Health Care
  • Exchange
  • IMUX Nasdaq
  • BYSI Nasdaq
  • Market Cap
  • IMUX 67.8M
  • BYSI 71.0M
  • IPO Year
  • IMUX N/A
  • BYSI 2017
  • Fundamental
  • Price
  • IMUX $0.69
  • BYSI $2.44
  • Analyst Decision
  • IMUX Strong Buy
  • BYSI
  • Analyst Count
  • IMUX 6
  • BYSI 0
  • Target Price
  • IMUX $11.60
  • BYSI N/A
  • AVG Volume (30 Days)
  • IMUX 2.6M
  • BYSI 151.5K
  • Earning Date
  • IMUX 08-07-2025
  • BYSI 08-11-2025
  • Dividend Yield
  • IMUX N/A
  • BYSI N/A
  • EPS Growth
  • IMUX N/A
  • BYSI N/A
  • EPS
  • IMUX N/A
  • BYSI N/A
  • Revenue
  • IMUX N/A
  • BYSI N/A
  • Revenue This Year
  • IMUX N/A
  • BYSI N/A
  • Revenue Next Year
  • IMUX N/A
  • BYSI N/A
  • P/E Ratio
  • IMUX N/A
  • BYSI N/A
  • Revenue Growth
  • IMUX N/A
  • BYSI N/A
  • 52 Week Low
  • IMUX $0.56
  • BYSI $0.98
  • 52 Week High
  • IMUX $2.11
  • BYSI $3.44
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 34.49
  • BYSI 51.78
  • Support Level
  • IMUX $0.68
  • BYSI $2.33
  • Resistance Level
  • IMUX $0.75
  • BYSI $2.62
  • Average True Range (ATR)
  • IMUX 0.06
  • BYSI 0.39
  • MACD
  • IMUX -0.00
  • BYSI -0.08
  • Stochastic Oscillator
  • IMUX 6.01
  • BYSI 10.30

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.

Share on Social Networks: